Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Clinical practice guidelines: non-Hodgkin's lymphomas

R I Fisher1, M M Oken

  • 1Division of Hematology/Oncology, Loyola University Medical Center, Maywood, IL 60153-5500, USA.

Cleveland Clinic Journal of Medicine
|January 1, 1995
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017).

Annals of oncology : official journal of the European Society for Medical Oncology·2017
Same author

Interferon in the Treatment of Refractory Multiple Myeloma: An Eastern Cooperative Oncology Group Study.

Leukemia & lymphoma·2016
Same author

The role of body mass index in survival outcome for lymphoma patients: US intergroup experience.

Annals of oncology : official journal of the European Society for Medical Oncology·2014
Same author

A phase II multicenter trial of hyperCVAD MTX/Ara-C and rituximab in patients with previously untreated mantle cell lymphoma; SWOG 0213.

Annals of oncology : official journal of the European Society for Medical Oncology·2013
Same author

Oral antibiotic prophylaxis of early infection in multiple myeloma: a URCC/ECOG randomized phase III study.

Leukemia·2012
Same author

A phase II trial of melphalan or thioguanine in the treatment of patients with advanced renal cell cancer.

Urologic oncology·2011

Treatment for non-Hodgkin's lymphomas (NHLs) varies by disease grade. While established therapies are mainstays, newer approaches like watchful waiting and high-dose chemotherapy with bone marrow transplantation show promise for advanced stages.

Area of Science:

  • Oncology
  • Hematology
  • Clinical Practice Guidelines

Background:

  • Non-Hodgkin's lymphomas (NHLs) exhibit diverse clinical behaviors despite a common clonal origin.
  • This heterogeneity complicates the development of standardized treatment protocols.

Purpose of the Study:

  • To review and compare historical and current data defining practice guidelines for NHL treatment.
  • To assess the efficacy of various therapeutic modalities across different NHL subtypes.

Main Methods:

  • Review of historical and contemporary clinical data and practice guidelines.
  • Comparative analysis of treatment outcomes for different grades and stages of NHL.

Main Results:

  • Early-stage, low-grade NHLs: Irradiation is the standard treatment.

Related Experiment Videos

  • Late-stage, low-grade NHLs: Alkylating agents are standard, with a 'watch-and-wait' approach emerging.
  • Intermediate/high-grade NHLs: Combination chemotherapy (e.g., CHOP) and irradiation are historical standards; bone marrow transplantation is an option for advanced disease.

    • Conclusions:

    • Current therapies remain primary treatments for NHLs.
    • Progressive regimens, including watchful waiting and high-dose chemotherapy with bone marrow transplantation, show success in specific patient groups.
    • Ongoing research explores novel agents like fludarabine and monoclonal antibodies for low-grade and advanced lymphomas.